

Johann von Felden

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8540604/publications.pdf>

Version: 2024-02-01

49
papers

2,942
citations

331670

21
h-index

276875

41
g-index

49
all docs

49
docs citations

49
times ranked

4210
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic variation in <i>TERT</i> modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study. <i>Gut</i> , 2023, 72, 381-391.	12.1	19
2	Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer. <i>Gut</i> , 2022, 71, 2069-2080.	12.1	24
3	Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFTY score. <i>Journal of Hepatology</i> , 2022, 76, 353-363.	3.7	132
4	Equal Efficacy and Safety Profile in Elderly Patients with Hepatocellular Carcinoma Receiving Palliative Treatment. <i>Cancers</i> , 2022, 14, 768.	3.7	1
5	Variants APOE (rs429358) and TM6SF2 (rs187429064) modify the risk of hepatocellular carcinoma. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, .	0.5	0
6	Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. <i>Hepatology</i> , 2022, 76, 1000-1012.	7.3	114
7	The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis. <i>Hepatology Communications</i> , 2022, 6, 1213-1226.	4.3	9
8	DNA Methylation Profiling of Human Hepatocarcinogenesis. <i>Hepatology</i> , 2021, 74, 183-199.	7.3	42
9	Sequential Systemic Treatment in Advanced Hepatocellular Carcinoma Is Able to Prolong Median Survival to More than 3 Years in a Selected Real-World Cohort. <i>Visceral Medicine</i> , 2021, 37, 87-93.	1.3	6
10	Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma. <i>Oncogene</i> , 2021, 40, 140-151.	5.9	77
11	Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1 infections. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 195-198.e2.	4.4	12
12	Experimental Models of Liquid Biopsy in Hepatocellular Carcinoma Reveal Clone-Dependent Release of Circulating Tumor DNA. <i>Hepatology Communications</i> , 2021, 5, 1095-1105.	4.3	7
13	Diagnostic and Prognostic Value of miR-16, miR-146a, miR-192 and miR-221 in Exosomes of Hepatocellular Carcinoma and Liver Cirrhosis Patients. <i>Cancers</i> , 2021, 13, 2484.	3.7	23
14	Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma. <i>PLoS Genetics</i> , 2021, 17, e1009589.	3.5	15
15	Rare variants of primary liver cancer: Fibrolamellar, combined, and sarcomatoid hepatocellular carcinomas. <i>European Journal of Medical Genetics</i> , 2021, 64, 104313.	1.3	19
16	Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers. <i>Hepatology</i> , 2020, 72, 88-102.	7.3	76
17	GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 728-735.e4.	4.4	167
18	Tumour evolution in hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 139-152.	17.8	501

#	ARTICLE	IF	CITATIONS
19	Liquid biopsy in the clinical management of hepatocellular carcinoma. <i>Gut</i> , 2020, 69, 2025-2034.	12.1	77
20	Elevated Aspartate Aminotransferase to Alanine Aminotransferase Ratio Predicts Poor Outcome in Hepatocellular Carcinoma. <i>Hepatology Communications</i> , 2020, 4, 1382-1383.	4.3	7
21	New systemic agents for hepatocellular carcinoma: an update 2020. <i>Current Opinion in Gastroenterology</i> , 2020, 36, 177-183.	2.3	17
22	Treatment and re-treatment results of HCV patients in the DAA era. <i>PLoS ONE</i> , 2020, 15, e0232773.	2.5	16
23	Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma. <i>Liver Transplantation</i> , 2020, 26, 823-831.	2.4	25
24	Intratumoral heterogeneity and clonal evolution in liver cancer. <i>Nature Communications</i> , 2020, 11, 291.	12.8	230
25	Real-life efficacy and safety profile of TACE in patients with intermediate HCC in a large German cohort. , 2020, 58, .		0
26	Retrospective evaluation of RFA and MWA for the treatment of HCC at the University Medical Center Hamburg 2008 – 2016. <i>Zeitschrift Fur Gastroenterologie</i> , 2020, 58, .	0.5	0
27	Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. <i>Gut</i> , 2019, 68, 1099-1107.	12.1	100
28	Reply to: “Burden of hepatitis E infection and associated healthcare resource utilization among hematological malignancy-related hospitalizations: A national perspective in the United States, 2007–2014”. <i>Journal of Hepatology</i> , 2019, 71, 1268-1269.	3.7	0
29	β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 1124-1141.	9.4	498
30	The burden of hepatitis E among patients with haematological malignancies: A retrospective European cohort study. <i>Journal of Hepatology</i> , 2019, 71, 465-472.	3.7	59
31	Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1323-1333.	3.7	106
32	The Impact of Translational Research in Hepatology. <i>Clinical Liver Disease</i> , 2019, 13, 29-33.	2.1	2
33	Chronic Hepatitis E in Rheumatology and Internal Medicine Patients: A Retrospective Multicenter European Cohort Study. <i>Viruses</i> , 2019, 11, 186.	3.3	34
34	Krankheitsverstandnis und Lebensqualitat von Patienten mit chronischer Hepatitis B (HBV) Infektion mit und ohne antivirale Therapie. <i>Zeitschrift Fur Gastroenterologie</i> , 2019, 57, .	0.5	0
35	Retherapie von Patienten mit chronischer Hepatitis-C Infektion nach Versagen einer Behandlung mit direct-acting agents (DAA). , 2019, 57, .		0
36	Carriage of HSD17B13 rs72613567TA is associated with a reduced risk for developing hepatocellular carcinoma in patients with alcohol-related cirrhosis. <i>Zeitschrift Fur Gastroenterologie</i> , 2019, 57, .	0.5	0

#	ARTICLE	IF	CITATIONS
37	PD-1 targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicenter real-world cohort. , 2019, 57, .		0
38	A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. <i>Oncogene</i> , 2018, 37, 3740-3752.	5.9	89
39	Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals. <i>Gastroenterology</i> , 2018, 154, 976-988.e4.	1.3	132
40	High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1288-1295.	3.7	46
41	Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis. <i>American Journal of Gastroenterology</i> , 2018, 113, 1475-1483.	0.4	82
42	Successful treatment of chronic hepatitis C with ground ledipasvir/sofosbuvir in a patient with Crohn's disease and short bowel syndrome. <i>Journal of Viral Hepatitis</i> , 2018, 25, 214-215.	2.0	6
43	Role of circulating tumor DNA to help decision-making in hepatocellular carcinoma. <i>Oncoscience</i> , 2018, 5, 209-211.	2.2	11
44	High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma. <i>Scientific Reports</i> , 2018, 8, 11570.	3.3	64
45	Editorial: genotype 3 HCV "who still needs ribavirin in a pan-genotypic era? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1550-1551.	3.7	1
46	High expression of micro RNA-135A in hepatocellular carcinoma is associated with recurrence within 12 months after resection. <i>BMC Cancer</i> , 2017, 17, 60.	2.6	24
47	Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection. <i>Oncotarget</i> , 2017, 8, 89978-89987.	1.8	58
48	Molecular profiling of liver cancer heterogeneity. <i>Discovery Medicine</i> , 2017, 24, 117-125.	0.5	3
49	First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma "An Update on Patient Selection and Response Evaluation. <i>Diagnostics</i> , 2016, 6, 44.	2.6	11